Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

(2021) Ola Landgren et al.   JAMA Oncology

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

(2021) Stefania Oliva et al.   Blood Cancer Journal

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

(2021) Benjamin Diamond et al.   Lancet Haematology

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

(2020) Luciano J. Costa et al.   BLOOD

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

(2020) Peter M Voorhees et al.   BLOOD

Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

(2020) Graham H. Jackson et al.   HAEMATOLOGICA

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

(2019) Hervé Avet-Loiseau et al.   Clinical Lymphoma Myeloma & Leukemia

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

(2019) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2019) Graham H Jackson et al.   Lancet Haematology

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

(2018) Manuela Gambella et al.   CANCER

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2018) Graham H Jackson et al.   LANCET ONCOLOGY

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

(2017) Philip L. McCarthy et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease as a Potential Surrogate End Point—Lingering Questions

(2017) Nicole J. Gormley et al.   JAMA Oncology

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis

(2016) O Landgren et al.   BONE MARROW TRANSPLANTATION

New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma

(2016) Ola Landgren et al.   CLINICAL CANCER RESEARCH

When the Minimal Becomes Measurable

(2016) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

(2015) A. C. Rawstron et al.   BLOOD

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

(2015) R. M. de Tute et al.   HAEMATOLOGICA

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

(2015) R. M. de Tute et al.   HAEMATOLOGICA

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter

(2011) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD